Transforming Oncology through Real-World Data
The promise of Real-World Data in oncology is clear - together, let's realize it for the benefit of patients worldwide. Our comprehensive Real-World Data solutions are ready to empower your organization's efforts and accelerate progress against cancer.
CIAN LUNG - Exploring the Potential of Real-Word Data in Lung Cancer Research
Our CIAN Lung initiative, a patient cohort focusing on non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), is an endeavor to leverage clinical and imaging datasets for qualitative and quantitative descriptive analyses, and aims to open new perspectives to enhance the accuracy of predictive and diagnostic computational models.
Advancing Value-Based Cancer Care
In our recent poster, we showcase how our technology enables data-driven insights into novel cancer therapies, evaluation of their real-life effectiveness and support of evidence-based decision-making in oncology. This lays the foundation for large scale trials and fosters collaboration towards improving cancer care outcomes globally.
Mikaela Bruhammar
Interim CEO
Mikaela has 20 years of experience in major global life-science companies, holding various strategic commercial and senior management positions in the Nordic region and globally. She worked at MSD Sweden AB (1999-2008), AstraZeneca Sweden and Nordic-Baltic (2008-2012), and was the Global Head of AstraZeneca’s Vaccine Franchise (2012-2015) and Vice President of the Nordic-Baltic Business Unit in RIA (2015-2019). In August 2019, she joined IQVIA, leading the EMEA Practice for Real World Data and Evidence solutions. She served as a board member at BC Platforms (2021-August 2023) and currently serves on the board of Ziccum AB. Mikaela holds an MSc in Molecular Biology from Linköping University, Sweden.
Alex Ide
EVP, Global Lead Life Science
Alex Ide, Executive Vice President (EVP), is the global lead for Life Science offerings. In his previous role at BC Platforms, he led the UK sales, driving the development and implementation of the company’s commercial strategy and growth in the UK. Alex is a healthcare executive with 20 years of experience in tech start-ups, large multinationals, and private partnerships. He has operated in functional leadership and business development roles across the scientific and commercial spectrums with global, regional, and national level clients at pharmaceutical, biotech, and medical device companies. Prior to BC Platforms, Alex worked at Prospection, IQVIA, and ZS. Alex holds an MChem Chemistry degree from The Queen’s College, University of Oxford.
Tero Oinonen
EVP, Marketing
Tero Oinonen, Executive VP, Marketing, has more than 30 years of experience from senior management positions in sales, marketing, and business development within the pharmaceutical and pharma service industry.
Prior to joining BC Platforms Tero worked at Novartis, AstraZeneca, and University of Helsinki and was the founding partner for a life sciences strategic consultancy company Spark Partners. Most recently, Tero led a contract research organization (CRO) called 4Pharma, which was acquired by BC Platforms in 2023, growing its capabilities in providing data intelligence analytics services to clients.
Tero holds an MBA degree from Henley UK and BSc in Engineering.
Alexandre Blanchot
Director, US Life Science
At BC Platforms, Alexandre promotes European Real World Data across diseases and advances the company's multi-modal value proposition to optimize clinical development. Alexandre has experience in drug development from discovery to commercialization, working with Gustave Roussy, AstraZeneca, and Genzyme on rare diseases. In Boston, he supported Life Sciences companies at Business France and the Innovation Centre of Denmark, focusing on public/private collaborations. He holds a Pharm D. from the University of Paris, an MBA in biotechnologies management from the Business School of Grenoble, and a certification in Business English Speaking from Boston University.